On December 9th, market news reported that Liu Yongjun, the Global R&amp;D President and Executive President of CSPC PHARMA (1093.HK), has resigned.
It is noteworthy that this comes just three months after Liu Yongjun joined the company—in September of this year, CSPC PHARMA officially announced Liu Yongjun's appointment, responsible for the group's R&amp;D, pipeline strategy, and international business development.
In this regard, TradeWind (ID:TradeWind01) has sought to verify the authenticity of the news with relevant personnel at CSPC PHARMA, who acknowledged awareness of the information but have not yet provided a definitive response on the matter.
Before joining CSPC PHARMA, Liu Yongjun was the President of Innovent Biologics (1801.HK).
Public reports indicate that prior to joining Innovent Biologics, Liu Yongjun served as the Global Head of Research at Sanofi.
He is also a Chinese scientist who has achieved the highest position in global multinational pharmaceutical companies in the R&amp;D field.
With such a distinguished background, there has been significant attention on whether Liu Yongjun can leverage his extensive global experience to create more opportunities for CSPC PHARMA's international expansion.
Currently, CSPC PHARMA still has several products, including JMT106 injection (a GPC3 and interferon receptor bispecific fusion protein), advancing clinical trials overseas.
At the same time, CSPC PHARMA is still working on transferring its innovative drug assets into its subsidiary, XinNuoWei (300765.SZ).
On December 8th, the Shenzhen Stock Exchange accepted XinNuoWei's application to issue shares to acquire 100% equity of CSPC PHARMA's innovative drug asset, CSPC Baike.
This comes nearly a year after XinNuoWei announced its restructuring in January of this year.
With Liu Yongjun's departure, the market continues to pay attention to who will succeed the positions of Global R&amp;D President and Executive President at CSPC PHARMA

01093

The president also needs a "probation period"

- On December 9, it was reported that Liu Yongjun, the global R&D president and CEO of CSPC Pharmaceutical Group (1093.HK), has left the company just three months after his appointment.  
- Prior to joining CSPC, Liu was the president of Innovent Biologics (1801.HK) and had previously held a global research leadership role at Sanofi.  
- The market is now focused on who will succeed Liu in his roles, as CSPC continues to advance several products in overseas clinical trials and is working on a significant asset acquisition involving its subsidiary, New Horizon (300765.SZ).

Wallstreetcn

CSPC PHARMA

Only three months after joining, CSPC PHARMA's Global R&D President Liu Yongjun "quickly" resigns?